LumiraDx Receives UK MHRA Approval for SARS-CoV-2 RNA STAR Complete

February 21, 2022 (London): LumiraDx (Nasdaq: LMDX) announced today that its rapid COVID-19 molecular assay, LumiraDx SARS-CoV-2 RNA STAR Complete, has been successfully validated by Coronavirus Test Device Approvals (CTDA) and received UK Medicines and Healthcare products Regulatory Agency (MHRA) approval. LumiraDx SARS-CoV-2 RNA STAR Complete, developed with proprietary qSTAR technology,...

LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant

London, UK (January 14, 2022): LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live Omicron virus demonstrated that the LumiraDx SARS-CoV-2 Antigen test detects...

LumiraDx CRP Test Achieves CE Marking

Rapid microfluidic immunofluorescence assay intended for the quantitative determination of C-reactive protein (CRP) in fingerstick, venous whole blood and plasma specimens within a range of 5.0 - 250.0 mg/L Quantitative results in 4 minutes from sample application, aids in fast clinical decision-making at the point of care (POC) Automated CRP...

LumiraDx Reports Third Quarter 2021 Financial Results

Strong Revenue Growth and Strategic Progress on Platform, Products and Pipeline London, UK (November 10, 2021), LumiraDx (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for the quarter ended September 30, 2021. • Revenue of $109.1M for the three months ended Sept. 30, 2021 and...

LumiraDx Announces FDA EUA Submission for its SARS-CoV-2 & Flu A/B Rapid Antigen Test

• Rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the simultaneous detection and differentiation of SARS-CoV-2, Influenza A, and Influenza B viral antigen • Results in 12 minutes from sample application, to allow for fast clinical decision-making at point of care (POC) •Available on the same...

El informe de guardametas de la Fundación Bill y Melinda Gates presenta el trabajo de LumiraDx en la lucha contra COVID-19

De la Fundación Bill y Melinda Gates: La respuesta del mundo al COVID-19 ha sido mucho más rápida que cualquier otra enfermedad en la historia. Para controlar el virus, el mundo necesita acceso a nuevas herramientas, como pruebas de diagnóstico rápidas, asequibles y precisas. Descubra cómo el dispositivo de prueba...

Translate »
topbar-lumiradx-popup
Estás apunto de ser redirigido a
www.lumiradx.com/uk-en/